Drug Profile

DWP 431

Alternative Names: Bongros-BMP; Bongros/BMP-2; DWP-431; Novosis; NOVOSIS-Dental; rhBMP-2

Latest Information Update: 03 Dec 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Daewoong Pharmaceutical
Developer Daewoong Pharmaceutical; HanAll Biopharma
Class Proteins
Mechanism of Action Bone morphogenetic protein 2 stimulants; Osteogenesis stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Marketed Alveolar bone loss; Spinal disorders

Most Recent Events

03 Dec 2021 Preclinical trials in Spinal disorders in USA (unspecified route), prior to December 2021 (Daewoong Pharmaceutical pipeline, December 2021)
12 May 2015 Phase III development is ongoing for Spinal disorders in South Korea
16 Apr 2013 Launched for Alveolar bone loss in South Korea (Intralesional)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com